

RENIN SECRETORY CAPACITY IN HEMODIALYSIS PATIENTS

THESIS

Submitted in Partial Fulfilment of
The Degree of M. S. in
GENERAL MEDICINE

By

MOSTAFA KAMEL MOHAMED

M. B; B. Ch.

Supervised by

Prof. Dr. WAHID MOHAMMED EL-SAID

Professor of Medicine

Dr. HUSSEIN EL-DAMASY

Ass. Prof. of Medicine

Faculty of Medicine
Ain Shams University

1983

CONTENTS

	<u>Page</u>
I. INTRODUCTION AND AIM OF THE WORK	1
II. REVIEW	2
. Historical note	2
. Physiology of Renin Angiotensin system.	4
. Renin Angiotensin System and hyperten- sion	19
. Renin Angiotensin system in acute renal failure	26
. Renin Angiotensin system in patients of chronic renal failure and end stage renal diseases on hemodialysis	28
. Value of measurement of PRA in hemodia- lysis patients	38
III. MATERIAL & METHODS	43
. Choice of the patients	43
. Tests done for the patients	43
. Preparation of the patients and precau- tions	44
. Principle of the test	47
. Statistical analysis	48
IV. RESULTS	50
V. DISCUSSION	67
VI. SUMMARY & CONCLUSION	77
VII. REFERENCES	79
VIII. ARABIC SUMMARY.	





ACKNOWLEDGEMENT

I would like to express my deepest gratitude and cordial thanks to Prof. Dr. Mohammed Wahid El-Said, Prof. of Medicine, Ain Shams University, for continuous guidance, encouragement, supervision and help that were always generously offered throughout this work.

I am deeply grateful to Dr. Hussein El-Damasy Ass. Prof. of Medicine for his illuminating advice and encouragement. He spent a lot of time guiding and directing me.

I want to thank the patients on dialysis and also all the workers in Ain Shams centre of hemodialysis for their extreme kindness and cooperation.

I would like also to thank Mr. Magdy Abbas and all the workers in the laboratory of the endocrinology department for their kindness and great help in the practical work of this thesis.

INTRODUCTION AND AIM OF THE WORK

INTRODUCTION AND AIM OF THE WORK

It is known that plasma renin level varies among patients with end stage renal failure. Some patients with renin dependant hypertension have severe hypertension which is difficult to control by hemodialysis (Schalekamp et al. 1973). For such patients bilateral nephrectomy have been advocated by some authers (Hampers et al. 1976). Others preferred the use of of vasodilators and antirenin drugs (Brown et al. 1976).

Because of the importance of renin, the work aimed at studying the aspects of renin secretion along one session heamodialysis as regards its pre and post-dialysis levels and their correlation to blood pressure, electrolyte changes, urea & creatinine levels, duration of hemodialysis and body weight. Also, the work aimed to give a short reveiw about the physiological and pathological aspects of renin.

R E V I E W

RENIN ANGIOTENSIN SYSTEMHISTORICAL NOTE

The idea that the kidneys may play a part in the genesis of certain types of hypertension originated from the observations of Richard Bright in 1827 in patients with nephritis. Further support for this idea came when Tigerstedt and Bergman in 1898 found that crude extract of the kidney when injected in experimental animals produced a rise in blood pressure. They called this pressor substance renin. (Skeggs et al. 1976).

In 1934 Goldblatt discovered that moderate reduction of renal blood flow by means of silver renal artery clamp produced persistent arterial hypertension "Goldblatt hypertension". Few years later investigators had detected the pressor activity of renal venous blood following renal artery constriction and had attributed this effect to renin (Douglas W.W. 1975).

In 1940 two groups, each working independently, Page and Helmer in the United States and Broun-Menedez in Argentina, showed that renin itself is not a direct

pressor agent, but they found that renin acts on plasma producing a vasoconstrictive substance. Page and Helmer called it angiotensin, Broun- Menedez called it hypertensin. In 1958 it was agreed to rename the pressor substance angiotensin and the plasma substrate angiotensinogen (Skeggs et al. 1976).

Peart and Skeggs in the period 1954 - 1958 isolated angiotensin from bovine plasma. Shortly after, Schwyzer and Bumpus were able to synthesize angiotensin. Gross in 1958 suggested that renin angiotensin system was involved in the electrolyte balance and aldosterone secretion by the adrenal cortex. Davis 1961, Ganong and Mulsow 1961 demonstrated that saline extract of kidney can stimulate aldosterone release (Douglas W.W. 1975).

Skeggs, was the first to detect angiotensin converting enzyme in the horse plasma (Skeggs et al. 1969).

Recently Blair-West et al. 1971, showed that a third form of angiotensin called angiotensin III may play a role though it had a weaker direct pressor effect.

PHYSIOLOGY OF
RENIN-ANGIOTENSIN SYSTEM

Renin is a proteolytic enzyme secreted by the kidney into the bloodstream. This glycoprotein has a molecular weight of 40,000 in humans. The kidneys and blood also contain a larger, relatively inactive renin, with a molecular weight of approximately 60,000. This protein, called prorenin, prerenin, big renin or simply inactive renin, is apparently the precursor of the active form. An even larger form (big big renin) has also been identified in renal tissue (Ganong, 1981).

Renin activity in the granular epitheloid cells was identified by immunofluorescent methods and a correlation was found between the granulation index and renin content of the kidney and Cook was able to remove granules from individual epitheloid cells and found that they contained renin (Black 1979).

Inactive renin is converted to active renin by tissue kallikrein then the active form acts on a glycoprotein in the α_2 globulin fraction of the proteins in

the circulating plasma, releasing a decapeptide, angiotensin I. The α_2 globulin is synthesized in the liver and is called angiotensinogen or renin substrate. Converting enzyme is a dipeptidyl carboxypeptidase that splits off histidyl-leucine from the physiologically inactive angiotensin I, forming the octapeptide angiotensin II (Ganong 1981).

Because the largest concentration of converting enzyme is found in the lung, it was until recently believed that conversion occurred only there (Ng & Vane 1967).

A specific converting enzyme was recently demonstrated to be present in the juxtaglomerular apparatus of the kidney (Granger et al. 1972). Lymph draining the kidney contains considerably higher concentrations of angiotensin II than are found in either arterial or renal venous blood. It must have been generated within the kidney (Bailie et al. 1971).

Angiotensin I has a half-life period of 80 minutes while angiotensin II has a shorter half-life of about 1-2 minutes. The enzymes that destroy angiotensin II are

collectively called **angiotensinase** which includes aminopeptidase that removes the aspergin residue from NH_2 terminus of the peptide. The heptapeptide produced is called **angiotensin III**, and has a physiological activity of $\frac{1}{4}$ to $\frac{1}{2}$ that of **angiotensin II**. Further hydrolysis to remove the next aminoacid arginin inactivates **angiotensin III** completely. Hydrolysis in the middle region by endopeptidases and C-terminal phenylalanine by carboxypeptidase fragments the compound completely (Ganong 1981).

Other organs produce other **angiotensin generating** enzymes with **renin** like activity include uterus, placenta, amniotic fluid & walls of blood vessels. These are called **isorenin** or **angiotensin generating** enzymes rather than **renin**. Their role is uncertain since plasma **renin** activity drops almost to zero when the kidneys are removed (Ganong 1981).

The sequence of reactions are illustrated in Fig. I.




Figure 1: Structure of angiotensins I, II, and III. R, remainder of protein. The structure shown is that of angiotensin II in humans, dogs, rats, and many other mammals. Bovine and ovine angiotensin II have valine instead of isoleucine in position 5.

Ganong 1981

Actions of angiotensins:

Angiotensin I has no known function apart from being, a precursor of angiotensin II (Ganong 1981).

Angiotensin II has the main effects of the renin angiotensin system as:

A) On the cardiovascular system:

On the heart angiotensin has a direct positive inotropic effect with weak chronotropic action but this occurs only in vitro while those effects are complicated by the indirect mechanisms controlling the heart in vivo (Dempsey et al. 1971).

On the blood vessels, angiotensin II produces arteriolar vasoconstriction and a rise of systolic and diastolic blood pressure being the most potent vasoconstrictor known. It is about 40 times more potent than norepinephrine (Ganong 1981).

Intravenous administration of angiotensin II produces vasoconstriction most marked in the vessels of the skin, splanchnic region and kidney. The precapillary vessels are the most affected, the postcapillary vessels

and veins are the least affected. The effect on the vessels of skeletal muscles, brain, heart & adrenal glands is moderate. The pulmonary vessels are not affected at all. The vascular response to angiotensin is due to two components, direct action on the smooth muscle fibres, and indirect action on the sympathetic nervous system (Beever et al. 1975). In man intravenous infusion of angiotensin causes vasoconstriction by direct action, but in certain vascular beds like the hand and foot, the vasoconstrictor action is mediated by the sympathetic effect and can be blocked by α -adrenergic blockers (Douglas W.W. 1975).

B) On the central Nervous system:

Angiotensin has a central sympathetic stimulatory action mainly on the area postrema in the medulla. It potentiates adrenergic transmission at peripheral neuroeffector setae, and facilitates ganglionic transmission and so modulates the sympathetic functions. Angiotensin can specifically stimulate drinking but not accompanied with eating so it increases water intake and stimulates the activity of supraoptic nuclei and secretion of ADH (Douglas W.W. 1975).